Objective-20-hydroxyeicosatetraenoic acid (20-HETE) promotes endothelial dysfunction by uncoupling endothelial NO synthase, stimulating O 2 − production, and reducing NO bioavailability. Moreover, 20-HETE-dependent vascular dysfunction and hypertension are associated with upregulation of the renin-angiotensin system This study was undertaken to examine the contribution of renin-angiotensin system to 20-HETE actions in the vascular endothelium. Methods and Results-In endothelial cells, 20-HETE induced angiotensin-converting enzyme (ACE) mRNA levels and increased ACE protein and activity by 2-to 3-fold; these effects were negated with addition of the 20-HETE antagonist, 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20 HEDE). 20-HETE induced ACE expression was protein kinase C independent and epidermal growth factor receptor tyrosine kinase and IκB kinase β dependent. ACE short interfering RNA abolished 20-HETE-mediated inhibition of NO production and stimulation of O 2 − generation, whereas angiotensin II type 1 receptor short interfering RNA attenuated these effects by 40%. 20-HETE-stimulated O 2 − production was negated by 20-HEDE and was attenuated by lisinopril and losartan. Importantly, 20-HETE-mediated impairment of acetylcholine-induced relaxation in rat renal interlobar arteries was also attenuated by lisinopril and losartan. 
T he synthesis of 20-hydroxyeicosatetraenoic acid , the ω-hydroxylation product of arachidonic acid, is catalyzed by enzymes of the cytochrome P450 4 (CYP4A) gene family. It is a potent vasoactive eicosanoid and a key constituent of the microcirculation, most notably, the renal and cerebral microcirculations. Its synthesis within the vascular wall is primarily localized to the smooth muscle cells, increased with decreased vessel diameter, stimulated by vasoactive hormones, such as angiotensin II (Ang II), endothelin, and norepinephrine, and inhibited by NO. 1 20-HETE elicits vasoconstriction largely via inhibition of the smooth muscle cell large conductance Ca 2+ -activated K + channel leading to depolarization and elevation in cytosolic [Ca 2+ ]. 2 It stimulates smooth muscle cell migration and proliferation 3, 4 and exerts actions on vascular endothelial function. 20-HETE is a potent angiogenic factor in vitro and in vivo [5] [6] [7] and a mitogen to endothelial cells, 8 as well as a modulator of endothelial NO synthase-NO production and function. [9] [10] [11] Changes in 20-HETE levels have been observed in pathological conditions including ischemic cerebrovascular diseases, cardiac ischemia-reperfusion injury, kidney diseases, hypertension, diabetes mellitus, and toxemia of pregnancy. 1 The vascular phenotype in many of these conditions is that of injury typified by endothelial dysfunction and activation. Recent studies in our laboratory provided substantial evidence that 20-HETE contributes to both endothelial dysfunction and endothelial activation associated with hypertension. In experimental models of increased vascular synthesis of 20-HETE, the resulting endothelial dysfunction, oxidative stress, and hypertension are prevented and reversed by administration of a 20-HETE synthesis inhibitor or a 20-HETE antagonist. [10] [11] [12] These actions of 20-HETE within the vascular wall are believed to constitute the mechanisms by which 20-HETE contributes to the development of hypertension.
In a recent study, we identified the angiotensin-converting enzyme (ACE) as one of the few genes that are markedly upregulated upon addition of 20-HETE to cultured endothelial cells. 13 Additional studies indicated that increased vascular synthesis of 20-HETE in vivo is also associated with increased vascular ACE expression and circulating Ang II levels. Moreover, in an experimental model of 20-HETEdependent hypertension, administration of ACE inhibitors or Ang II type 1 receptor (AT 1 R) blockers prevented and reversed the blood pressure elevation in response to increased vascular 20-HETE levels. 13 These findings provided a novel paradigm where excessive production of 20-HETE within the vasculature, such as in androgen-induced hypertension, leads to hypertension via mechanisms that include the induction of endothelial ACE, thus perpetuating an increase in vascular Ang II, which in turn and together with 20-HETE, promotes vascular dysfunction.
The current study was undertaken to further determine the cellular mechanisms by which 20-HETE induces ACE and to evaluate whether ACE is a needed component for 20-HETE actions in the vasculature and, in particular, in the endothelium. Here, we demonstrate that in endothelial cells, 20-HETE induces ACE via epidermal growth factor receptor (EGFR) and IκB kinase (IKK) activation and that 20-HETE-mediated inhibition of NO and stimulation of O 2 − production, as well as 20-HETE-mediated impairment of relaxation to acetylcholine in renal microvessels are influenced by ACE and Ang II-AT 1 R activation.
Methods and Materials

Cell Culture
Human microvascular endothelial cells (HMVECs) were grown in Medium 131 containing 5% microvascular growth supplement (Invitrogen, Carlsbad, CA) and 5% fetal bovine serum (USA Scientific, Ocala, FL). Passages 3-5 were used for all experiments. Cells were maintained at 37°C in a humidified incubator with an atmosphere of 5% CO 2 :95% O 2 . For most experiments, cells were grown in 6-well plates to 80%-90% confluence and placed in serum-free media for 24 hours before addition of compounds. Compounds used in this study are the following For NO measurements, cells were preincubated with 20-HETE (5 nmol/L) or its vehicle (0.1% ethanol) for 2 hours and treated with or without calcium ionophore A23187 (5 μmol/L) in the presence of L-arginine (25 μmol/L) for 30 minutes. NO levels were measured using a NO quantitation kit (Active Motif, Carlsbad, CA), and cGMP levels were measured by immunoassay (R&D systems, Minneapolis, MN). 10, 14 For O 2 − measurements, cells were treated with or without Tiron (10 mmol/L), 20-HETE (5 nmol/L), 20-HEDE (5 nmol/L), angiotensin II (100 nmol/L), losartan (10 μmol/L), and lisinopril (10 μmol/L) for 2 hours. O 2 − levels were measured using dihydroethidium (DHE) (5 μmol/L) (Calbiochem, Gibbstown, NJ) as described. 14 
Agonist-Induced Vasorelaxation
All experimental protocols were approved by the Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (n=3-5) aged 7 to 8 weeks old were used. Acetylcholine-induced relaxation was measured using renal interlobar arteries as described. 11, 14 Arteries were incubated in the presence and absence of 20-HETE (1 μmol/L), lisinopril (10 μmol/L), and losartan (10 μmol/L) for 2 hours, after which they were preconstricted with phenylephrine (5 μmol/L), and the relaxing responses to increasing concentrations (5×10 
Statistical Analysis
Data are expressed as means±SEM. Significance of difference in mean values was determined using t test and 1-way ANOVA, followed by the Newman-Keul post hoc test. P<0.05 was considered to be significant.
Results
20-HETE Increases ACE Expression and Angiotensin II Production in Endothelial Cells
Addition of 20-HETE (5 nmol/L) to HMVECs resulted in a time-dependent induction of ACE mRNA expression with a maximal 2.5-fold increase at 2 hours ( Figure 1A ). The increase in ACE mRNA expression was abrogated by cotreatment with an equimolar concentration of 20-HEDE, a 20-HETE antagonist, 15 suggesting that the increase in ACE expression is 20-HETE dependent. The effect of 20-HETE on ACE mRNA was observed over a wide range of concentrations with a significant 2.5-and 3-fold induction at 1 and 5 nmol/L, respectively, and a maximum induction of 4-fold at 10 nmol/L ( Figure 1B ). Additional experiments comparing the effect of 20-HETE and the known ACE inducer phorbol 12-myristate 13-acetate 16 clearly indicated that, whereas phorbol 12-myristate 13-acetate significantly increased ACE mRNA 24 hours after its addition, the increase in ACE mRNA in response to 20-HETE was maximal at 2 hours ( Figure Figure 1C) . Moreover, the increase in ACE protein was negated by coaddition of the 20-HETE antagonist 20-HEDE ( Figure 1D ). Addition of 20-HETE to HMVECs stimulated cellular and extracellular ACE activity by 2-fold at 24 hours. Importantly, the 20-HETE-mediated increase in ACE activity was blocked by addition of 20-HEDE (5 nmol/L) and was inhibited by lisinopril (100 nmol/L), suggesting that the increase in ACE activity is 20-HETE dependent ( Figure 1E ).
The vascular wall, including the endothelium, expresses components of the renin-angiotensin system (RAS), including angiotensinogen, renin, ACE, ACE2, AT 1 R, and AT 2 R. 17 Realtime polymerase chain reaction analysis revealed that 20-HETE at 5 nmol/L increased angiotensinogen mRNA by 2.2-fold at 2 hours. At the same time frame, 20-HETE did not affect levels of ACE2 mRNA but did reduce AT 1 R and AT 2 R expression by 30% to 40% ( Figure 18 Therefore, we examined whether 20-HETE-mediated ACE induction is also tyrosine kinase and IKKβ dependent. Pretreatment with either 2-[(3,4,5-trihydroxyphenyl) methylene]-propanedinitrile, a tyrosine kinase inhibitor specific for EGFR, or 4-amino-[2,3'-bithiophene]-5-carboxamide, a specific IKKβ inhibitor, prevented 20-HETE from increasing ACE expression. The PKC inhibitor calphostin C had no effect on 20-HETE-induced ACE mRNA ( Figure  2A ) or ACE activity (Figure VIB in the online-only Data Supplement). 11,12-epoxyeicosatrienoic acid, an endothelialderived cytochrome P450 eicosanoid which has been shown to activate EGFR in endothelial cells, 19 had no effect on ACE mRNA ( Figure IIIB in the online-only Data Supplement).
To ascertain that 20-HETE-mediated ACE induction is dependent on IKKβ activation, a specific IKKβ short interfering RNA (siRNA) was used. IKKβ siRNA suppressed the expression of IKKβ by 70±6% and ACE by 49±7% when compared with control siRNA ( Figure 2B ). Furthermore, incubation with IKKβ siRNA prevented 20-HETE-mediated induction of ACE, whereas incubation with the control siRNA had no effect on 20-HETE-induced ACE expression; in the latter, ACE expression in response to 20-HETE increased by 2.5-fold ( Figure 2C ). 
Effect of ACE and AT1R Knockdown on 20-HETE-Mediated Inhibition of NO and Stimulation of O 2 − Production
We have shown that in short-term experiments, 20-HETE inhibits NO production (and cGMP production, Figure . In longterm conditions, it also stimulates NADPH oxidase activity and increases O 2 − , which is rapidly converted to H 2 O 2 in some cells. 8, 11, 20 The role of ACE induction in 20-HETE-mediated NO inhibition and O 2 − production was assessed using ACEand AT 1 R-specific siRNAs. In cells transfected with the ACE siRNA, ACE mRNA was reduced by 42%, whereas levels of AT 1 R mRNA were unaffected. Transfection of cells with AT 1 R siRNA reduced AT 1 R mRNA by 47% but had no significant effect on ACE mRNA ( Figure 3A) . As expected, in cells transfected with the ACE siRNA, 20-HETE failed to increase ACE mRNA but did decrease AT 1 R mRNA by 45% (P<0.05). However, in cells transfected with the AT 1 R siRNA, 20-HETE had no further effect on AT 1 R mRNA, whereas its inducing effect on ACE was unaffected; ACE mRNA increased by 2-fold in response to 20-HETE in AT 1 R siRNA-transfected cells ( Figure 3A) . The efficacy of the siRNAs was further confirmed by Western blot ( Figure 3B ).
The effect of downregulating ACE and AT 1 R expression on the 20-HETE-mediated NO production is shown in Figure 3C . Treatment of cells with 20-HETE inhibited ionophore-stimulated NO production by 11.7-and 6.3-fold in nontransfected and control siRNA-transfected cells, respectively. ACE siRNA transfection negated the ability of 20-HETE to inhibit NO production. However, 20-HETEmediated inhibition of NO production was attenuated by 40% in AT 1 R siRNA-transfected cells ( Figure 3C ), suggesting that Ang II contributes to 20-HETE-mediated inhibition of NO production via AT 1 R-dependent mechanisms.
The effect of downregulation of ACE and AT 1 R expression on the 20-HETE-mediated increase in O 2 − formation is depicted in Figure 3D . 20-HETE increased Tiron-sensitive O 2 − levels by 306±43% and 260±25% in nontransfected and control siRNAtransfected cells, respectively. Downregulation of ACE expression abolished the increase in O 2 − levels by 20-HETE but had no effect on basal levels of O 2 − . However, knockdown of AT 1 R expression had no effect on basal O 2 − levels but did reduce 20-HETE-stimulated O 2 − production by 40% ( Figure 3D ). Under the same conditions, 20-HETE had no effect on H 2 O 2 levels in HMVECs ( Figure IXB in the online-only Data Supplement).
Effects of ACE Inhibition and AT 1 R Blockade on 20-HETE-Stimulated O 2 − Production
Ang II has been shown to stimulate O 2 − production in vascular cells, including endothelial cells. Therefore, its contribution to 20-HETE-mediated O 2 − production was further evaluated using lisinopril and losartan. As shown in Figure 4A , incubation of cells with Ang II increased O 2 − production to levels similar to that achieved with 20-HETE. Although addition − levels by 40% but had no effect on O 2 − production in response to Ang II. Lisinopril and losartan had no significant effect on O 2 − production in the absence of 20-HETE or Ang II ( Figure 4A ). These results further support the notion that Ang II contributes to the 20-HETE-mediated stimulation of O 2 − production.
20-HETE-Mediated Impairment in AcetylcholineInduced Vasorelaxation Is Partially Restored With Inhibitors of ACE and AT 1 R
The results in endothelial cells suggested that ACE and AT 1 R may play a role in the 20-HETE-mediated inhibition of acetylcholine-induced relaxation. As shown in Figure 4B 
Discussion
The relationship between RAS and 20-HETE has been suggested in several studies but has not been fully elucidated. Ang II has been shown to stimulate the synthesis of 20-HETE in isolated human neutrophils and platelets 21 and in rat kidney and preglomerular vessels. 22, 23 In hypertensive humans, increased plasma levels of 20-HETE are correlated with increased plasma renin activity, 24 whereas in high-salt diet-fed rats in which the RAS is suppressed, CYP4A expression is reduced. 25 Other studies demonstrated that increased 20-HETE in the peripheral vasculature contributes to the acute vasoconstrictor response to Ang II, 26 whereas acute and chronic inhibition of 20-HETE synthesis, attenuates the renal pressor response to Ang II, 22 and the development of Ang II-dependent hypertension. 27 20-HETE is known to mediate Ang II-induced mitogenic effects in cultured aortic vascular smooth muscle cells and contribute to the vascular injury, hypertrophy, and hypertension caused by Ang II in rats. [28] [29] [30] Interestingly, experimental models of hypertension that show increased vascular 20-HETE production, such as the spontaneously hypertensive rats 31, 32 and the androgen-induced hypertensive rats, 11, [33] [34] [35] are also RAS mediated. The nature of these interactions is yet to be fully identified. In a recent study, we showed that endothelial-specific CYP4A2 expression produced 20-HETEdependent hypertension, 36 which was abrogated by either AT 1 R blockade or ACE inhibition. 13 Based on these findings and data from microarray analysis indicating that 20-HETE is a potent inducer of endothelial ACE, we postulated that excessive production of 20-HETE within the vasculature leads to hypertension via mechanisms that include the induction of endothelial ACE, thus perpetuating an increase in vascular Ang II, which in turn and together with 20-HETE promotes vascular dysfunction. The mechanisms and the extent to which ACE contributes to 20-HETE-mediated vascular endothelial dysfunction are explored in the current study.
Endothelial cells are known to express most of the components of the RAS, including angiotensinogen, ACE, ACE2, AT 1 R, and AT 2 R. Moreover, the endothelium has been shown to actively participate in the vascular production of Ang II, 17, 37, 38 which, in turn, alters endothelial function by increasing the production of reactive oxygen species, most prominently O 2 − , and decreasing NO bioavailability. The vascular endothelium is also a target for the actions of 20-HETE, where it interferes with NO synthesis and stimulates O 2 − production. 14, 20, 39 We have recently demonstrated that, in endothelial cells, 20-HETE uncouples endothelial NO synthase via an EGFR-mitogen-activated protein kinase-IKKβ signaling pathway leading to decreased NO levels and increased O 2 − production. 14, 18 Furthermore, in the long-term, 20-HETE also increases O 2 − production by activating NADPH oxidase. 11 Here, we demonstrated that 20-HETE induces ACE expression and increases its activity, an effect abrogated by cotreatment with the 20-HETE antagonist 20-HEDE. The ability of 20-HETE to increase ACE mRNA within 2 hours and the demonstration that inhibition of EGFR or IKKβ activation, both of which mediate 20-HETE actions in endothelial cells, 18 abolished the ability of 20-HETE to increase ACE mRNA levels further points to the specificity of 20-HETE effect and suggests a novel mechanism not shared with known ACE inducers, such as phorbol 12-myristate 13-acetate and vascular endothelial growth factor. 16, 40 Phorbol 12-myristate 13-acetate-activated PKC has been shown to increase ACE mRNA level and ACE gene transcription, as well as ACE secretion in human umbilical vein endothelial cells. 41 The demonstration that a PKC inhibitor had no effect on 20-HETE-mediated increases in ACE mRNA and activity further substantiate the notion of a distinct mechanism for 20-HETE actions on ACE expression and activity. Moreover, the fact that 11,12-epoxyeicosatrienoic acid, which has been shown to activate EGFR in endothelial cells, 19 does not induce ACE mRNA suggests that activation of IKK downstream of EGFR is a key feature of 20-HETE action. A recent study demonstrated that inhibition of IKK activation in vivo abrogates 20-HETE-dependent vascular dysfunction and hypertension. 42 The mechanism that links activation of EGFR-IKK and possibly nuclear factor-kappa B (NF-κB), the downstream effector molecule of IKKβ activation, to ACE expression is unclear. There are no reports regarding the presence of NF-κB response elements on the ACE promoter, and studies to examine the effect of NF-κB inhibition on intrarenal RAS expression in a model of proteinuric renal injury suggested that ACE expression is not subjected to regulation by NF-κB. 43 However, IKKβ and NF-κB may activate a distinct ACE-responsive transcriptional pathway, such as activator protein 1. A connection between NF-κB and activator protein 1 has been documented, 44 and activator protein 1 has been shown to activate the transcription of endothelial ACE. 16 Clearly, further studies are needed to fully understand the mechanism by which 20-HETE induces endothelial ACE.
This study demonstrated that induction of ACE expression and activity is an important mechanism by which 20-HETE affects endothelial and vascular function. In cells transfected with ACE siRNA, 20-HETE-mediated inhibition of NO and stimulation of O 2 − production were completely prevented. However, suppression of AT 1 R expression by siRNA attenuated but did not prevent the 20-HETE-mediated effects on NO and O 2 − production, suggesting that Ang II actions through the AT 1 R (eg, stimulation of NADPH oxidase) 45 are required but not necessary for achieving the maximum effect of 20-HETE. As for ACE, it is possible that its induction by 20-HETE elicits actions independent of Ang II and its actions through the AT 1 R such as degradation of bradykinin, a key mediator of NO production in the endothelium and a substrate for ACE. 46 However, we cannot exclude the possibility that ACE contribution could be independent of its catalytic activity. 47 Certainly, additional studies are needed to fully determine the mechanism by which ACE affects 20-HETE. The use of lisinopril and losartan to inhibit ACE activity and block the AT 1 R, respectively, provided additional evidence that ACE and AT 1 R contribute to the stimulatory effect of 20-HETE on O 2 − levels. In addition, treatment of renal interlobar arteries with either lisinopril or losartan improved the 20-HETE-induced impairment in relaxation response to acetylcholine, an effect that has been attributed to 20-HETE-induced reduction in NO production through endothelial NO synthase uncoupling. 10, 14 We also found that 20-HETE induces angiotensinogen expression in endothelial cells. Angiotensinogen is transcriptionally activated by NF-κB, and the IKK-NF-κB pathway may be the mechanism by which 20-HETE induces its expression. All together, the ability of 20-HETE to induce angiotensinogen in the same time frame as ACE suggests that 20-HETE contributes to activation of the RAS at multiple points. It also raises the possibility that 20-HETE perpetuates at least 2 positive feedback loops. As shown in Figure 5 , there are several ways by which the initial response to 20-HETE can be amplified. We argue that ACE induction is an important component of 20-HETE-induced endothelial and vascular dysfunction.
We further postulate that induction of endothelial ACE sets in motion a functional amplification circuit that combines the actions of 20-HETE, ACE (generation of Ang II and degradation of bradykinin), and Ang II (reactive oxygen speciesderived endothelial dysfunction, vasoconstriction), and further increases vascular dysfunction. The ability of 20-HETE to increase angiotensinogen expression provides an additional amplification of the aforementioned processes. The relevance of this study to human health is supported by numerous reports indicating a correlation between urinary 20-HETE, oxidative stress, and endothelial dysfunction in hypertensive subjects, 48, 49 as well as associations among CYP4F2 (a major 20-HETEsynthesizing enzyme in humans) polymorphisms and hypertension 50, 51 and ischemic stroke. ), respectively. 14, 18 The activation of IKKβ through EGFR-and MAPK-dependent pathways also constitute the mechanism by which 20-HETE induces angiotensin-converting enzyme (ACE) expression, leading to increased ACE activity. The increase in O 2 − levels in response to 20-HETE is initially the consequence of eNOS uncoupling 8, 14 and later the result of activation of NADPH oxidase. 8, 11 20-HETE may also stimulate, either directly or indirectly through the NF-κB-activated pathway, the expression of angiotensinogen (AGT). The induction of ACE alone and together with AGT can lead to increases in the vascular production of angiotensin (Ang II), which through its interaction with AT 1 R, further amplifies 20-HETE actions on the endothelium, namely, decreases in NO bioavailability and increases in O 2 − levels, thus exacerbating endothelial dysfunction and impeding on vascular function.
